How the choice of a good research site can impact the success of your clinical investigation in medical devices
When a sponsor begins planning a clinical investigation, it is common for the focus to be on the protocol, timeline, and regulatory objectives of the study. But there is one decision that can directly influence this entire process: the choice of the research site.
In practice, the site is not just the place where the study takes place. It is where the protocol begins to be executed, where data starts to be generated, and where the conduct of the study truly demonstrates its consistency. Therefore, choosing an appropriate site can impact recruitment, data quality, protocol adherence, and regulatory predictability. Good clinical practices outlined in ISO 14155 reinforce precisely the importance of conducting clinical investigations with a focus on participant protection and the credibility of results.
The right site goes beyond execution
It is common to look at factors such as location, patient volume, or previous research experience. All of this is important, but in studies with regulatory purposes, it is not enough.
A good research site must also have a prepared team, infrastructure compatible with the study, organized documentation, and the ability to conduct the protocol with quality. Even with a well-planned study, failures in local execution can generate deviations, inconsistencies in data, and rework.
In other words, the site does not only impact the operation of the study ? it influences the reliability of the evidence that will be generated.
What to evaluate when choosing a site
Some points usually make a difference in this decision:
Experience with the study profile: more than having a research background, ideally the site should be familiar with the type of investigation proposed.
Operational capacity: team availability, well-structured routines, and support for conducting the study make a difference in day-to-day activities.
Documentation quality: complete, traceable, and well-organized records help sustain the credibility of the data.
Quality recruitment: it is not enough to include participants quickly; it is necessary to ensure adherence to protocol criteria.
Regulatory maturity: sites with good responses to pending issues, deviations, and monitoring tend to bring more predictability to the study.
When this choice is not well made
The impacts of an inadequate site do not always appear at the beginning. Often, they arise gradually: delays, recurring pending issues, protocol deviations, documentation failures, and difficulty maintaining data consistency.
For the sponsor, this may mean more time spent on corrections, more strain in conducting the study, and greater regulatory risk.
In the case of medical devices, this care is very important. ANVISA has updated the rules for clinical investigations with medical devices through RDC 837/2023, maintaining the requirement for approval through the DICD process (Clinical Investigation Dossier for Medical Devices) for investigations whose results may support the registration of Class III and IV devices. This reinforces the importance of well-structured studies from the beginning.
A strategic decision for the success of the study
When site selection is carried out with technical criteria, risk awareness, and alignment with the regulatory objective, the sponsor gains more than just a place to execute the protocol. They gain more predictability, more consistency in execution, and greater confidence in the quality of the data generated.
Therefore, the choice of the research site should be treated as a strategic decision from the very beginning of the clinical investigation.
If your company is looking for specialized support to structure clinical investigations with greater safety, quality, and regulatory alignment, contact us at contact@grinn.co
